Lyell Immunopharma Inc
NASDAQ:LYEL

Watchlist Manager
Lyell Immunopharma Inc Logo
Lyell Immunopharma Inc
NASDAQ:LYEL
Watchlist
Price: 25.54 USD -1.16% Market Closed
Market Cap: $542m

Operating Margin

-491 609.8%
Current
Declining
by 259 066.9%
vs 3-y average of -232 542.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-491 609.8%
=
Operating Income
$-201.6m
/
Revenue
$41k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-491 609.8%
=
Operating Income
$-201.6m
/
Revenue
$41k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Lyell Immunopharma Inc
NASDAQ:LYEL
492.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 14 112 companies
1st percentile
-491 609.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Lyell Immunopharma Inc
Glance View

Market Cap
542m USD
Industry
Biotechnology

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 219 full-time employees. The company went IPO on 2021-06-17. The firm offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. The company builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). The company offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. The company utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

LYEL Intrinsic Value
0.58 USD
Overvaluation 98%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-491 609.8%
=
Operating Income
$-201.6m
/
Revenue
$41k
What is Lyell Immunopharma Inc's current Operating Margin?

The current Operating Margin for Lyell Immunopharma Inc is -491 609.8%, which is below its 3-year median of -232 542.8%.

How has Operating Margin changed over time?

Over the last 3 years, Lyell Immunopharma Inc’s Operating Margin has decreased from -562.1% to -491 609.8%. During this period, it reached a low of -491 609.8% on Oct 30, 2025 and a high of -215% on Mar 31, 2023.

Back to Top